drugset / Trial / NCT02603705

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

NCT02603705

Phase 3 Completed 281 enrolled Egalet Ltd
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.

Timeline

Start
2016-03-07
Primary completion
2017-06-15
Completion
2017-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxycodone Other / unclassified

Indications

No indication recorded.